Analysis of six novel flavin-containing monooxygenase 3 (FMO3) gene variants found in a Japanese population suffering from trimethylaminuria

Makiko Shimizu, Yumi Origuchi, Marika Ikuma, Nanako Mitsuhashi, Hiroshi Yamazaki *

Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, 3-3165 Higashi-tamagawa-Gakuen, Machida, Tokyo 194-8543, Japan

A R T I C L E   I N F O
Article history:
Received 14 October 2015
Received in revised form 31 October 2015
Accepted 31 October 2015
Available online 7 November 2015

Keywords:
Flavin-containing monooxygenase 3
Fish odor syndrome
Trimethylamine
Polymorphism
Japanese
Trimethylaminuria

A B S T R A C T
Polymorphic human flavin-containing monooxygenase 3 (FMO3) is associated with the inherited disorder trimethylaminuria. Several FMO3 variants have been observed in a variety of ethnic groups, including a Japanese cohort suffering from trimethylaminuria. The aim of this study was to screen another self-reported Japanese trimethylaminuria cohort for novel FMO3 variants and to investigate these new variants. Subjects with low FMO3 metabolic capacities were identified by measuring the urinary trimethylamine and trimethylamine N-oxide concentrations in 171 Japanese volunteers. The FMO3 genes from these subjects and their family members were then sequenced. Heterozygotes or homozygotes for novel single-nucleotide polymorphisms or abolished functional activities with respect to trimethylamine metabolism-reports/trimethylaminuria were identified. In addition, the known (but as yet uncharacterized) single-nucleotide polymorphism c.929 C>T p.(Ser310Leu) was found. Pedigree analysis revealed the p.(Ser310Leu) FMO3 allele in cis configuration with c.929 C>T p.(Glu158Lys). These variant FMO3 proteins recombinantly expressed in Escherichia coli membranes exhibited decreased N-oxygenation activities toward trimethylamine and benzylamine. Although the allele frequencies of these seven variants were low, the present results suggest that individuals homozygous or heterozygous for any of these novel missense or duplication/FMO3 variants or known nonsense mutations such as p.(Cys197Ter) may possess abnormal activities toward trimethylamine N-oxygenation.

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Polymorphic human flavin-containing monooxygenase 3 (FMO3, EC 1.14.13.8) is associated with the inherited disorder trimethylaminuria [1,2]—the inability to metabolize odorous dietary-derived trimethylamine to its non-odorous N-oxide [3,4]. Rare loss-of-function mutations [1] that cause the disorder have been reported. Decreased or abolished functional activities with respect to trimethylamine N-oxygenation, resulting in trimethylaminuria, are caused mainly by single nucleotide polymorphisms of the FMO3 gene. Such FMO3 polymorphisms have been reported in the literature [5–9]. FMO3 mutations resulting in the amino acid substitutions p.(Glu158Lys), p.(Val257Met), and p.(Glu308Gly) have been reported as common FMO3 gene variants in the International HapMap project (http://www.hapmap.org) in multiple ethnic populations. Differences in terms of frequency of occurrence of the FMO3 variants have been recognized in Caucasian and Asian populations [10].

We previously analyzed the function of six novel FMO3 variants in 640 Japanese volunteers with self-reported trimethylaminuria [3]. Currently, Japanese subjects (from different families) with trimethylaminuria are known to possess p.(Cys197Ter), p.(Arg205Cys), and p.(Arg500Ter) FMO3 alleles with frequencies in the range of 2–4%. Minor FMO3 variants p.(Val58Ile), p.(Pro70Leu), p.(Asn114Ser), p.(Glu158Lys;Thr201Lys), p.(Glu158Lys;Thr201Lys;Glu308Gly), p.(Glu158Lys;Glu470Ter), p.(Ser195Leu), p.(Val257Met;Met260Val), p.(Val257Met;Thr388Ter), p.(Val257Met;Thr388Ter), p.(Val257Met;Thr388Ter), p.(Val257Met;Thr388Ter), and p.(Thr488Ala) have also been found in Japanese cohorts [3,4,8,10–14].

In our 2012 report, we screened and investigated 640 Japanese volunteers with self-reported trimethylaminuria [3]; in this current study, we screened and investigated novel FMO3 variants in a further 171 Japanese volunteers with self-reported trimethylaminuria. We report herein six new FMO3 variants with impaired trimethylamine N-oxygenation as causal factors for trimethylaminuria in a Japanese population.

2. Materials and methods

The basic experimental methods for screening urinary trimethylamine and trimethylamine N-oxide concentrations, sequencing
the FMO3 gene from buccal cells obtained from volunteer subjects suffering from self-reported body malodor, and recombinantly expressing FMO3 variant proteins in bacterial membranes were described previously [3,4]. The current investigation is a follow-up study to our 2012 report [3] with a new group of 171 subjects ranging from 1 to 93 years of age; informed consent was obtained from each subject or parent of the subject. The ethics committees of Showa Pharmaceutical University approved this study.

Genotyping analysis for the novel mutations was carried out by allele-specific polymerase chain reaction (PCR) methods or PCR-restriction fragment length polymorphism (RFLP) methods, as shown Table 1, with DNA amplified using the primers described previously [15]. RFLP digestions were carried out at 37°C for 2 h using the designated restriction enzymes. The primers for allele-specific PCR methods for p.(Ile7Thr), p.(Phe43Ile), and p.(Glu287AspfsTer17) variants are listed in Table 2. Trimethylamine, trimethylamine O-nitroxide, benzylamine, benzylamine O-nitroxide, and other reagents were from sources described previously [3].

3. Results

3.1. DNA analysis of probands 1–8

FMO3 metabolic capacity (% of total trimethylamine excreted as trimethylamine O-nitroxide) was determined in volunteers with self-reported trimethylaminuria. The frequency of subjects with less than 40% FMO3 metabolic capacity (severe trimethylaminuria) was 11% (20 of 171 subjects) in a Japanese population with self-reported trimethylaminuria. We focused on eight of the participants who had low to moderate metabolic capacities for trimethylamine O-nitroxide (Table 3). In proband 1, who had 29% FMO3 metabolic capacity (Table 3), DNA sequencing of the ancestral type FMO3 variant in bacterial membranes was described previously [3,4]. The current investigation is a follow-up study to our 2012 report [3] with a new group of 171 subjects ranging from 1 to 93 years of age; informed consent was obtained from each subject or parent of the subject. The ethics committees of Showa Pharmaceutical University approved this study.

Genotyping analysis for the novel mutations was carried out by allele-specific polymerase chain reaction (PCR) methods or PCR-restriction fragment length polymorphism (RFLP) methods, as shown Table 1, with DNA amplified using the primers described previously [15]. RFLP digestions were carried out at 37°C for 2 h using the designated restriction enzymes. The primers for allele-specific PCR methods for p.(Ile7Thr), p.(Phe43Ile), and p.(Glu287AspfsTer17) variants are listed in Table 2. Trimethylamine, trimethylamine O-nitroxide, benzylamine, benzylamine O-nitroxide, and other reagents were from sources described previously [3].

3. Results

3.1. DNA analysis of probands 1–8

FMO3 metabolic capacity (% of total trimethylamine excreted as trimethylamine O-nitroxide) was determined in volunteers with self-reported trimethylaminuria. The frequency of subjects with less than 40% FMO3 metabolic capacity (severe trimethylaminuria) was 11% (20 of 171 subjects) in a Japanese population with self-reported trimethylaminuria. We focused on eight of the participants who had low to moderate metabolic capacities for trimethylamine O-nitroxide (Table 3). In proband 1, who had 29% FMO3 metabolic capacity (Table 3), DNA sequencing of the ancestral type FMO3 variant in bacterial membranes was described previously [3]. The current investigation is a follow-up study to our 2012 report [3] with a new group of 171 subjects ranging from 1 to 93 years of age; informed consent was obtained from each subject or parent of the subject. The ethics committees of Showa Pharmaceutical University approved this study.

Genotyping analysis for the novel mutations was carried out by allele-specific polymerase chain reaction (PCR) methods or PCR-restriction fragment length polymorphism (RFLP) methods, as shown Table 1, with DNA amplified using the primers described previously [15]. RFLP digestions were carried out at 37°C for 2 h using the designated restriction enzymes. The primers for allele-specific PCR methods for p.(Ile7Thr), p.(Phe43Ile), and p.(Glu287AspfsTer17) variants are listed in Table 2. Trimethylamine, trimethylamine O-nitroxide, benzylamine, benzylamine O-nitroxide, and other reagents were from sources described previously [3].

Table 1

| Variant | Position with respect to accession number | Exon | Restriction enzyme for PCR products | Length (bp) of RFLP products, uncut/cut (fragment) |
|---------|-------------------------------------------|------|-------------------------------------|---------------------------------|
| p.(Ile7Thr) | g.5736 T>C | 2 | Allele specific (-cat/-cac) | 186 |
| p.(Trp41Ter) | g.5838 G>A | 2 | SfI | 519/273 + 246 (mutant) |
| p.(Phe43Ile) | g.5843 T>A | 2 | Allele specific (-aat/-aaa) | 256 |
| p.(Leu163Pro) | g.21140 T>C | 5 | Sau96I | 699/473 + 226 (mutant) |
| p.(Glu287AspfsTer17) | g.27086-27096dupTTTAACCAGTA | 7 | - | 464/475 |
| p.(Ser310Leu) | g.27165 C>T | 7 | EcoT14I | 345 + 119/149 + 196 + 119 (mutant) |
| p.(Gly376Glu) | g.27363 G>A | 7 | EcoT14I | 345 + 119/464 (mutant) |

Table 2

| Variant | Primer name | Allele-specific primer |
|---------|-------------|-----------------------|
| p.(Ile7Thr) | Forward | hFMO3 Ile7Thr wild |
| p.(Trp41Ter) | Forward | hFMO3 Ile7Thr mutant |
| p.(Phe43Ile) | Forward | hFMO3 Phe43Ile wild |
| p.(Glu287AspfsTer17) | Forward | hFMO3 Phe43Ile mutant |
| p.(Ile7Thr) | Reverse | hFMO3ex2AS |
| p.(Trp41Ter) | Reverse | hFMO3ex2AS |
| p.(Phe43Ile) | Reverse | hFMO3ex2AS |
| p.(Glu287AspfsTer17) | Reverse | hFMO3ex2AS |

Urinary trimethylamine O-nitroxide analysis of both parents and another brother of proband 1 showed that their FMO3 metabolic capacity was greater than 90%, in contrast to the <30% metabolic capacity of proband 1 and his brother.

In proband 2, who possessed 31% FMO3 metabolic capacity, we found the novel c.1277→A FMO3 variant p.(Phe43Ile) (Fig. 1B) and the novel variant c.1127G>A FMO3 p.(Gly376Glu) (Fig. 1C) (Table 3). DNA sequencing of FMO3 in samples from proband 2’s family (Fig. 2B) revealed that proband 2 and her mother were heterozygous for p.(Phe43Ile) allele and proband 2 and her father were heterozygous for the p.(Gly376Glu) allele. As shown in Table 1, allele-specific PCR and PCR-RFLP methods were developed for p.(Phe43Ile) and p.(Gly376Glu), respectively. These methods could successfully identify the respective FMO3 variants. The PCR product from the ancestral allele at codon 376 is digested by EcoT14I into 345- and 119-bp fragments, whereas the variant allele is not digested. In probands 3 and 4, we found p.(Gly376Glu) alleles, respectively (Fig. 2C). Probands 3 and 4 had FMO3 metabolic capacities of 19% and 90%, respectively (Table 3). These individuals were also heterozygous for the known variants p.(Cys197Ter) and p.(Gly158Lys;Glu306Gly) [8], respectively (Table 3).

We found a duplication (TTTAACCAGTA) polymorphism at the c.850-860 position of FMO3 variant p.(Glu287AspfsTer17) (Fig. 1D) in proband 5, who possessed 24% FMO3 metabolic capacity (Table 3). The sequence of this duplication was identical to c.850–860 in exon 7 of ancestral type FMO3. Pedigree analysis disclosed that the p.(Glu287AspfsTer17) allele was in the trans configuration with p.[Val257Met;Trp388Ter] (Fig. 2D). The PCR product lengths from this duplication variant were longer than those of the ancestral allele using the primers shown in Table 2. The mother and sister of proband 5 had this duplication variant, as reconfirmed by this new method.

Another new FMO3 variant, c.929C>T p.(Ser310Leu) (Fig. 1E), was found in proband 6, who possessed 15% FMO3 metabolic capacity (Table 3). Pedigree analysis revealed this p.(Ser310Leu) FMO3 allele to be in the cis configuration with p.(Glu158Lys) (Fig. 2E). On DNA sequencing the FMO3 genes from this family, we found that proband 6 and her father and sister were heterozygous for the p.[Glu158Lys;Ser310Leu] allele (Fig. 2E). As shown in Table 1, a PCR-RFLP method was developed for the p.(Ser310Leu) allele using EcoT14I. This method was the same as that for the p.(Gly376Glu) variant. The PCR product from the mutant allele at codon 310 was digested by EcoT14I into 149-, 146-, and 119-bp fragments. Urinary analysis of
both parents and the sister of proband 6 showed that their FMO3 metabolic capacities were greater than 80%, in contrast to the 15% metabolic capacity of proband 6. We found other novel variants\(c.20T\rightarrow N\)(Ile7Thr)\(\) (Fig. 1F) in proband 7 and\(c.488T\rightarrow N\)(Leu163Pro)\(\) (Fig. 1G) in proband 8. Proband 7, who was heterozygous for the above new variant and known mutation\(p.(Arg205Cys)\), had 49% FMO3 metabolic capacity (Table 3). Proband 8 was homozygous for the above novel mutation and had 32% in vivo FMO3 metabolic capacities (Table 3). The simple allele-specific PCR or PCR-RFLP methods shown in Table 1 were developed and were able to identify these seven FMO3 variants.

The allele frequencies of\(p.(Ile7Thr)\), \(p.(Trp41Ter)\), \(p.(Phe43Ile)\), \(p.(Leu163Pro)\), \(p.(Glu287AspfsTer17)\), \(p.(Ser310Leu)\), and \(p.(Gly376Glu)\) FMO3 alleles were 0.3% (1 of 342 alleles), 0.3% (1 of 342 alleles), 0.6% (1 of 342 alleles), and 0.6% (1 of 342 alleles), respectively, in the current Japanese cohort (excluding family members). Although the existence of\(p.(Trp41Ter)\), \(p.(Glu287AspfsTer17)\), and \(p.(Ser310Leu)\) FMO3 alleles was confirmed in the family of probands 1, 5, and 6, the apparent allele frequencies given above were calculated among unrelated subjects.

### 3.2. Enzyme activities of recombinant FMO3 variants

The kinetic parameters for the functional activities of recombinantly expressed variant FMO3 proteins with respect to trimethylamine and benzydamine\(N\)-oxygenation were determined by nonlinear regression analysis; these parameters were compared with those of wild type FMO3 expressed in bacterial membranes (Table 4). The apparent\(K_m\) values of the FMO3 variants, except for\(p.(Ile7Thr)\) and\(p.(Gly376Glu)\), were approximately the same as that for wild type FMO3. However, the apparent\(K_{cat}\) and\(K_{cat}/K_m\) values of the FMO3 variants were approximately in the range one-half to one-twentieth of that of the wild-type enzyme (Table 4). FMO3 variants\(p.(Ile7Thr)\), \(p.(Glu158Lys;Ser310Leu)\), and\(p.(Gly376Glu)\) had less than 10% of wild-type trimethylamine\(N\)-oxygenation activity.

### 4. Discussion

A human FMO3 database [16] has been established (http://databases.lovd.nl/shared/genes/FMO3) by scientists in the United Kingdom and contains known causative FMO3 variants of trimethylaminuria [10, 17]. In the current study, six novel FMO3 variants with impaired trimethylamine and benzylamine\(N\)-oxygenation

---

**Table 3**

| Proband | Age/gender (years) | Genotype | FMO3 metabolic capacity, % |
|---------|--------------------|----------|----------------------------|
| 1       | 12, M              | p.(Cys197Ter);(Tryptophan17) | 29 |
| 2       | 6, F               | p.(Phe43Ile);(Gly376Glu)     | 31 |
| 3       | 42, M              | p.(Phe43Ile);(Cys197Ter)     | 19 |
| 4       | 5, M               | p.(Glu158Lys;Glu308Gly)      | 90 |
| 5       | 4, M               | p.(Val257Met;Tryptophan38Ter);(Glu287AspfsTer17) | 24 |
| 6       | 7, F               | p.(Glu158Lys;Ser310Leu);(Cys197Ter) | 15 |
| 7       | 21, F              | p.(Arg205Cys);(Ile7Thr)      | 49 |
| 8       | 37, M              | p.(Leu163Pro);(Leu163Pro)    | 32 |

---

**Fig. 1.** Nucleotide sequences of variant FMO3. Both strands were sequenced. The sequences are shown only for sense strands of genomic DNA from probands 1 (A), 2 and 3 (B), 2 and 4 (C), 5 (D), 6 (E), 7 (F), and 8 (G). The sequence of the complete human FMO3 gene described in GenBank (Accession Number AL021026) was used as the reference.
capacity were discovered in a Japanese population with self-reported trimethylaminuria; these variants are likely causative of trimethylaminuria (Fig. 1). In addition to these six novel FMO3 variants, FMO3 p.(Ser310Leu) (rs572292275) was also found in our cohort. This FMO3 variant has been reported in a Portuguese population[18], but no functional analysis has yet been carried out. In the current study, p.(Glu158Lys;Ser310Leu) FMO3 variant was found in a familial analysis; this variant exhibited extremely impaired trimethylamine and benzydamine N-oxygenation capacity (Table 4). An FMO3 protein truncated at position 303 resulted from the 10-base duplication in variant p.(Glu287AspfsTer17). The functional importance of the C-terminus of human FMO3 was clearly indicated by our previous findings that recombinant p.(Arg500Ter) FMO3 expressed in bacterial membranes showed no detectable functional activity toward trimethylamine. These results suggest that individuals harboring the nonsense FMO3 mutations p.(Trp41Ter), p.(Cys197Ter), p.(Val257Met;Trp388Ter), and p.(Glu287AspfsTer17) will likely exhibit abnormally low levels of trimethylamine N-oxygenation.

The eight probands in this study were heterozygotes or homozygotes for novel or known FMO3 variants (Fig. 1) and did not efficiently N-oxygenate dietary-derived trimethylamine to its N-oxide (Table 3). The impaired levels of trimethylamine N-oxygenation evident in the in vivo phenotype (Table 3) were most likely caused by the combination of these known and/or novel FMO3 variants (Table 4).

![Fig. 2. Pedigree analysis for the presence of novel FMO3 variants in probands 1 (A), 2 (B), 4 (C), 5 (D), and 6 (E).](image)

**Table 4**

Functional activities of wild-type and variant FMO3 recombinantly expressed in E. coli.

| Variant FMO3 | N-oxygenation | Benzydamine |
|--------------|---------------|-------------|
|              | Trimethylamine |             |             |
|              | Km, μM | Vmax, min⁻¹ | Kcat/Km | Km, μM | Vmax, min⁻¹ | Kcat/Km |
| Wild-type    | 70 ± 9 | 50 ± 2 | 0.7 (100) | 58 ± 5 | 197 ± 4 | 3.4 (100) |
| 7Thr         | 429 ± 215 | 2.4 ± 0.6 | 0.006 (0.9) | 50 ± 6 | 0.73 ± 0.02 | 0.02 (0.6) |
| 43Ile        | 46 ± 9 | 6.5 ± 0.24 | 0.14 (20) | 40 ± 5 | 0.33 ± 0.5 | 0.07 (14) |
| 163Pro       | 60 ± 15 | 19 ± 1 | 0.31 (44) | 59 ± 9 | 90 ± 4 | 1.5 (44) |
| 158Lys;310Leu| 83 ± 20 | 1.6 ± 0.1 | 0.02 (3) | 61 ± 4 | 59 ± 1 | 0.97 (29) |
| 376Glu       | 33 ± 18 | 1.2 ± 0.1 | 0.03 (4) | 22 ± 7 | 0.27 ± 0.02 | 0.01 (0.3) |

The substrates (0–500 μM trimethylamine and 0–1000 μM benzydamine) were incubated with recombinant FMO3 (50 and 5 pmol Eq for trimethylamine and benzydamine oxygenations) at 37 °C for 30 and 10 min, respectively, in the presence of an NADPH-generating system. Kinetic parameters were calculated from a fitted curve by nonlinear regression (mean ± SE). Values in parentheses are percentages of the wild type value.
In conclusion, subjects carrying heterozygous/homozygous combinations of any of the nonsense or missense mutated FMO3 alleles found in this study, together with those previously reported, probably possess FMO3 with reduced trimethylamine N-oxygenation efficiency and thus may suffer from severe or mild trimethylaminuria.

Acknowledgments

We thank all the volunteers for their participation in this study. We also thank Dr. Norie Murayama, Dr. Shotaro Uehara, Asaki Kase, Chiaki Toyokawa, Sayaka Tomoda, Marie Goto, Miki Makino, and Emi Tokumoto for their help, and David Smallbones for his English advice. This work was supported in part by the Japan Society for the Promotion of Science KAKENHI Grant Number 25460198.

References

[1] C.T. Dolphin, A. Jamnogehed, R.L. Smith, E.A. Shephard, I.R. Phillips, Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome, Nat. Genet. 17 (1997) 491–494.
[2] C.K. Allerston, H.H. Vetti, C. Houge, I.R. Phillips, E.A. Shephard, A novel mutation in the flavin-containing mono-oxygenase 3 gene (FMO3) of a Norwegian family causes trimethylaminuria, Mol. Gen. Genomics. 98 (2009) 198–202.
[3] M. Shimizu, Y. Kobayashi, S. Hayashi, Y. Aoki, H. Yamazaki, Variants in the flavin-containing mono-oxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population, Mol. Genet. Metab. 107 (2012) 330–334.
[4] M. Shimizu, C.K. Allerston, E.A. Shephard, H. Yamazaki, I.R. Phillips, Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population, Br. J. Clin. Pharmacol. 77 (2014) 839–851.
[5] B.R. Akerman, H. Lemass, L.M. Chow, D.M. Lambert, C. Greenberg, C. Bibeau, O.A. Mamer, E.P. Treacy, Trimethylaminuria is caused by mutations of the FMO3 gene in a North American cohort, Mol. Genet. Metab. 68 (1999) 24–31.
[6] D.M. Lambert, O.A. Mamer, B.R. Akerman, L. Choiniere, D. Gaudet, P. Hamet, E.P. Treacy, In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene, Mol. Genet. Metab. 73 (2001) 224–229.
[7] E. Teresa, F. Lonardo, A. Fiumara, C. Lombardi, P. Russo, C. Zuppi, G. Scarano, S. Musumeci, F. Gianfrancesco, A spectrum of molecular variation in a cohort of Italian families with trimethylaminuria: identification of three novel mutations of the FMO3 gene, Mol. Genet. Metab. 88 (2006) 192–195.
[8] H. Yamazaki, H. Fujita, T. Gunji, J. Zhang, T. Kamataki, J.R. Cashman, M. Shimizu, Stop codon mutations in the flavin-containing mono-oxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population, Mol. Genet. Metab. 90 (2007) 58–63.
[9] M.S. Motika, J. Zhang, X. Zheng, K. Riedler, J.R. Cashman, Novel variants of the human flavin-containing mono-oxygenase 3 (FMO3) gene associated with trimethylaminuria, Mol. Genet. Metab. 97 (2009) 128–135.
[10] H. Yamazaki, M. Shimizu, Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities, Biochem. Pharmacol. 85 (2013) 1588–1593.
[11] M. Shimizu, H. Fujita, T. Aoyama, H. Yamazaki, Three novel single nucleotide polymorphisms of the FMO3 gene in a Japanese population, Drug Metab. Pharmacokinet. 21 (2006) 245–247.
[12] M. Shimizu, S. Tomiska, N. Murayama, H. Yamazaki, M. Miyazaki, Nonsense variant and nonsense mutations of the flavin-containing monooxygenase 3 gene in a Japanese cohort, Drug Metab. Pharmacokinet. 22 (2007) 61–64.
[13] C.K. Allerston, M. Shimizu, M. Fujieda, E.A. Shephard, H. Yamazaki, I.R. Phillips, Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3), Pharmacogenet. Genomics 17 (2007) 827–839.
[14] H. Yamazaki, M. Shimizu, Genetic polymorphism of the flavin-containing monooxygenase 3 (FMO3) associated with trimethylaminuria (fish odor syndrome): observations from Japanese patients, Curr. Drug Metab. 8 (2007) 487–491.
[15] M. Kubota, Y. Nakamoto, K. Nakayama, P. Ujjin, S. Satarug, T. Mushiroda, T. Yokoi, M. Funayama, T. Kamataki, A mutation in the flavin-containing monooxygenase 3 gene and its effects on catalytic activity for N-oxidation of trimethylamine in vitro, Drug Metab. Pharmacokinet. 17 (2002) 207–213.
[16] D. Hernandez, S. Addou, D. Lee, C. Orengo, E.A. Shephard, I.R. Phillips, Trimethylaminuria and a human FMO3 mutation database, Hum. Mutat. 22 (2003) 209–213.
[17] E.A. Shephard, E.P. Treacy, I.R. Phillips, Clinical utility gene card for: trimethylaminuria — update 2014, Eur. J. Hum. Genet. 23 (2015).
[18] F. Ferreira, S. Esteves, L.S. Almeida, A. Gaspar, C.D. da Costa, P. Janeiro, A. Bandeira, E. Martins, J.L. Teles, P. Garcia, L. Vilarinho, Trimethylaminuria (fish odor syndrome); genotype characterization among Portuguese patients, Genet. Select. (2013) 366–370.